Significant Ownership of Clearline Capital LP

Signature - Title
Marc Majzner - Limited Partner
Location
New York, NY
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Clearline Capital LP.

Follow Filing Activity

Follow Clearline Capital LP and return when a new Schedule 13D/G filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.

Significant Ownership of Clearline Capital LP

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
HRTX HERON THERAPEUTICS, INC. /DE/ Common Stock, par value $0.01 per share 6.7% $18,108,154 +$3,733,614 12,235,239 +26% Clearline Capital LP 31 Dec 2025
XPER Xperi Inc. Common Stock (par value $0.001 per share) 6.4% $17,787,867 2,949,895 Clearline Capital LP 31 Dec 2025
TXMD TherapeuticsMD, Inc. Common Stock, par value $0.001 per share 5.5% $705,096 635,222 Clearline Capital LP 31 Dec 2024
MX MAGNACHIP SEMICONDUCTOR Corp Common Stock, par value $0.01 per share 4.1% $3,725,642 -$1,119,807 1,461,036 -23% Clearline Capital LP 31 Dec 2025

Schedules 13D/G Reported by Clearline Capital LP:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .